With the launch, the company has become the first Indian and second global firm to develop the drug, Mankind Pharma said in a statement. The company's product is generic version of Abbott's Duphaston tablets, it added. The manufacturing process of Dydrogesterone is very complex as it involves conversion of natural progesterone, the statement said.
NASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatment of NASH. aroglitazar Mg has previously demonstrated improvement in both liver enzymes along with favorable effects on lipid and glycemic indices in patients with nonalcoholic fatty liver disease in Phase II clinical trials.
The biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologics is chasing a revenue target of $1 billion in financial year 2021-22. In the previous fiscal year, its revenue had topped $200 million.
Strides Pharma Global Pte Ltd, Singapore, has received tentative approval for Diclofenac Potassium Softgel Capsules, 25 mg from the United States Food & Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.
Sequent’s market cap as on Tuesday was Rs 1,670 crore. But the founders are seeking a control premium of 49.7% or 18-20x forward Ebitda multiple, valuing the company at Rs 2,100-2,500 crore, sources said. Some, however, worry that such expectations may turn out to be a potential deal breaker.
"We want India to come up with a progressive e-pharmacy regulation. We want that as that would give a lot of clarity and confidence to the sector, whether it is investors, whether it is our business partners and vendors," 1mg Technologies Founder and CEO Prashant Tandon told reporters here. The government is yet to release the final notification.
Ogivri, available in a 420mg multi-dose vial and a 150mg single-dose vial, will be used for treatment of all types of breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).
Drug major Sun Pharma is a defendant in a multi-district litigation brought by various classes of plaintiffs in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs -- Valganciclovir, Valsartan and Esomeprazole. The company said it would continue to vigorously defend against all claims.
The Biocon subsidiary will chart a path that ensures high volumes and low costs, unlike competitors. The company plans to create an ecosystem where patients not only have access to the right medicine, but also gets the right care without always reaching a hospital.
A Roche India spokesperson confirmed the development and said an announcement for a new India head will be made soon. “Dec. 1 will be the date for Lara to end the assignment. During her tenure at Roche India, Lara successfully led the organization with passion and commitment and shaped the culture of the organization,”the statement added.